BioPharmSignal logoBioPharmSignal

Biotech News

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

Lyra Therapeutics (LYRA)Lyra TherapeuticsSEC filing

WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the "SEC") on Monday, April 20, 2026, to remove its common stock from

Related news

LYRALyra Therapeutics2025-06-27 12:00 EST

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

LYRALyra Therapeutics2025-06-02 11:00 EST

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

View all latest news

Lyra Therapeutics

Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease. Its platform uses localized delivery to treat difficult ENT conditions.

Recent company news

LYRALyra Therapeutics2026-04-17 12:00 EST

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

LYRALyra Therapeutics2026-01-12 12:00 EST

Lyra Therapeutics Provides Corporate Update

LYRALyra Therapeutics2025-11-12 21:01 EST

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

LYRALyra Therapeutics2025-10-06 11:00 EST

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

LYRALyra Therapeutics2025-08-12 20:01 EST

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
0.01 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States